CellCept Pure Red Cell Aplasia Reports Lead to New Warnings
The FDA announced Friday that labeling for the organ transplant medication CellCept will be changed to add warnings that the drug could cause a type of anemia known as Pure Red Cell Aplasia (PRCA).
Roche Laboratories, Inc., which manufactures CellCept (mycophenolate mofetil), notified healthcare professionals last week that it was making revisions to the drug’s warning label after receiving reports of 41 users who developed Pure Red Cell Aplasia as a possible side effect of CellCept.
CellCept is an immunosuppressant medication approved for treatment of transplant patients and is taken to keep the body from rejecting a new organ. It is usually used with other immunosuppressant drugs. CellCept is also often prescribed for off-label uses, such as the treatment of lupus.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
Pure Red Cell Aplasia (PRCA) is a type of anemia that affects the precursors to red blood cells, causing bone marrow to cease to produce red blood cells. Symptoms of PRCA include fatigue, lethargy, and abnormal paleness of the skin. Treatments include cessation of any drug causing the condition and corticosteroids. PRCA is not considered a condition that significantly increases mortality.
The notice from Roche to healthcare professionals noted that in 16 of the 41 cases reported, reduction of dose or cessation of the use of CellCept resulted in a resolution of the condition. However, the company warned that healthcare professionals should consider the combination of drugs the patient is taking, and take the risk of organ rejection into account before ceasing use of CellCept.
There is already a “black box” warning carried on the medication’s label for lymphoma and potential CellCept birth defects. The medication warns that females of child-bearing age must use contraceptives while on CellCept, as women who use the medication and continue taking it into the first trimester of pregnancy could expose their child to an increased risk of birth defects, such as cleft palate, cleft lip and ear deformities.
CellCept side effects have also been connected to a potential increased risk of a rare brain infection known as Progressive Multifocal Leukoencephalopathy or PML, which affects the central nervous system. There is no known cure for the brain infection and it is fatal in many cases.
"*" indicates required fields
More Top Stories
A federal judge has approved a plan appointing several dozen plaintiffs' attorneys to leadership positions in Bard Port Catheter litigation.
A ProPublica report reveals that Philips officials hid thousands of reports of problems with sound abatement foam used in millions of CPAP machines, failing to recall the devices for more than a decade after receiving the first complaints.
A Suboxone lawsuit claims the opioid addiction treatment's dental side effects can lead to severe tooth damage and decay.